Tawny Kitaen, the sultry red-haired actress who appeared in rock music videos during the heyday of MTV, has died.

The estranged father of actor Lindsay Lohan has been arrested on charges that he illegally took kickbacks for referring patients to a Florida substance abuse treatment center.

FILE - In this Friday, Jan. 22, 2021 file photo, empty vials of the Pfizer-BioNTech COVID-19 vaccine are seen at a vaccination center at the University of Nevada, Las Vegas in Las Vegas. (AP Photo/John Locher)With demand for COVID-19 vaccines outpacing the world’s supplies, a frustrated public and policymakers want to know: How can we get more? Makers of COVID-19 vaccines need everything to go right as they scale up production to hundreds of millions of doses — and any little hiccup could cause a delay. “It’s just not that easy.”DIFFERENT VACCINES, DIFFERENT RECIPESThe multiple types of COVID-19 vaccines being used in different countries all train the body to recognize the new coronavirus, mostly the spike protein that coats it. But possibly the easiest way to get more doses is if other vaccines in the pipeline are proven to work.

Researchers expressed concern Wednesday about the preliminary findings, in large part because they suggest that future mutations could undermine vaccines. One way vaccines work is to prompt the immune system to make antibodies that block the virus from infecting cells. The Rockefeller researchers got blood samples from 20 people who had received either the Moderna or Pfizer vaccine and tested their antibodies against various virus mutations in the lab. The slower we roll out vaccine around the world, the more opportunities we give this virus to escape” and develop mutations, he said. Moderna and AstraZeneca, which makes a different type of COVID-19 vaccine used in some countries, also have been testing how their vaccines hold up against different mutations.

How could scientists race out COVID-19 vaccines so fast without cutting corners? A head start helped -- over a decade of behind-the-scenes research that had new vaccine technology poised for a challenge just as the coronavirus erupted. Both shots -- one made by Pfizer and BioNTech, the other by Moderna and the National Institutes of Health -- are so-called messenger RNA, or mRNA, vaccines, a brand-new technology. U.S. regulators are set to decide this month whether to allow emergency use, paving the way for rationed shots that will start with health workers and nursing home residents. Traditionally, making vaccines required growing viruses or pieces of viruses — often in giant vats of cells or, like most flu shots, in chicken eggs — and then purifying them before next steps in brewing shots.

Many scientists dont expect a coronavirus vaccine to be nearly as protective as the measles shot. If the best COVID-19 vaccine is only 50% effective, "thats still to me a great vaccine, said Dr. Drew Weissman of the University of Pennsylvania. About 15 experimental COVID-19 vaccines are in various stages of human studies worldwide. Nothing is going to be easy.The Oxford shot, with a 10,000-person study underway in England, already encountered that hurdle. EXPECT IMPERFECT PROTECTIONAnimal research suggests COVID-19 vaccines could prevent serious disease but may not completely block infection.